Improving health system cash flows through 340B program optimization and strategic management of drug spend and pricing structure

Hospitals and health systems must continue to find ways to reduce expenses and improve revenue and recover positive cash flows. One area many organizations are turning to is their pharmacy departments with 340B Drug Program optimization and strategic management of drug spend and pricing structure. By conducting a review of their organization’s 340B participation, compliance, and pharmacy pricing and charge structures, many health system leaders are finding additional ways to reduces expenses and right-size their pharmaceutical charges, while taking better control of their reimbursement structure with contracted payers. 

Join Baker Tilly for an informative webinar where our team of healthcare specialists will discuss how health systems can conduct a review of their organizational 340B participation, 340B compliance program, revenue cycle compliance for pharmacy charges, and strategic pricing optimization for their pharmacy charges to help improve their bottom line. Finally, our team will walk through actual use cases showing how one system was able to recertify for 340B participation reducing costs by nearly $12 million annually and another hospital that identified more than $11 million in annual gross charge improvement with significant anticipated increases in net revenue.  

 Who should attend?  

• C-Suite executives, presidents, VPs, and directors, as well as pharmacy leaders and revenue cycle professionals at hospitals and health systems  

Presenters  

• Keith Hutcheson, Partner, Baker Tilly 
• Ed Ricks, MHA, CHCIO, Managing Director, Baker Tilly 
• Anne Jones, RPh, Senior Pharmacy Consultant, Baker Tilly 
• Sherri Faber, RPh, MHA, 340B ACE 

Learning objectives  

• Gain insights on 340B participation and reclassification opportunities 
• Learn about 340B Compliance programs 
• Gain insights into how health systems can optimize their pharmacy charges through conducting a comprehensive pharmacy charge review, including their 340B Drug Pricing Program and Commercial Payers 
• Recognize actionable steps after areas of improvement have been identified 
• Explore real case studies highlighting significant reductions in expense and optimization of charges leading to significant increases in reimbursement by their contracted payers